Skip to Content

    Investors are betting big on ­Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-­disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.

    41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Overall Score2.5
    Health Care
    Leonard S. Schleifer
    HQ Location
    Tarrytown, N.Y.
    Revenues ($M) (Past 12 Months)$5,236
    Profits ($M) (Past 12 Months)$1,155
    Market Value as of Oct. 9, 2017 ($M)$50,054